<DOC>
	<DOCNO>NCT00567554</DOCNO>
	<brief_summary>Anthracycline-taxane base chemotherapy regimen recommend mainly current guideline neoadjuvant application systemic treatment . The addition cytotoxic agent , e.g . antimetabolite , vincaalkaloids , platinum salt result marginal increase efficacy , associate also increase toxicity . Recently , addition Her-2 antibody trastuzumab significantly improve pathologic response rate . Therefore , two major strategy follow current research project : - To improve selection patient accord tumor ' sensitivity chemotherapy . - To implement small molecule specific mechanism action . Within GeparQuinto trial , first strategy follow : - The PREDICT substudy . A gene signature specific response anthracyclines taxanes prospectively evaluate ability identify patient chance high 50 % pCR . The result may leed good risk-benefit ratio use conventional chemotherapy . - Adapting chemotherapy response tumor first couple chemotherapy cycle . Based previous experience make GeparTrio study , patient respond early low chance respond pCR irrespective type chemotherapy . So , chemotherapy plan , therapy select accord favorable toxicity profile . The second strategy follow investigate three parallel group comparison efficiency three distinct small molecule appear generally active breast cancer : - Bevacizumab , inhibitor VEGF pathway target tumor neo-angiogenesis . - Lapatinib , inhibitor Her-1 Her-2 receptor tyrosine kinase . - RAD001 ( Everolimus ) , inhibitor mTOR molecule , central controller tumor cell growth angiogenesis chemosensitizer . Treatment patient participate GeparQuinto study allocate accord Her-2 status tumor well accord sonographic response first 4 cycle treatment . Experimental therapy bevacizumab , lapatinib , everolimus ( RAD001 ) randomly add distinct setting .</brief_summary>
	<brief_title>Bevacizumab , Everolimus ( RAD001 ) , Lapatinib Neoadjuvant Chemotherapy Regimes Primary Breast Cancer</brief_title>
	<detailed_description>Primary objective : To compare pCR rate neoadjuvant treatment epirubicin / cyclophosphamide follow docetaxel ( EC-T ) without bevacizumab ( EC-T vs. ECB-TB ) patient Her-2 negative primary breast cancer ( Setting I ) . To compare pCR rate neoadjuvant treatment weekly paclitaxel without Everolimus ( RAD001 ) ( Pw vs. PwR ) patient Her-2 negative primary breast cancer show sonographic response 4 cycle EC +/-B ( Setting II ) . To compare pCR rate neoadjuvant treatment epirubicin / cyclophosphamide follow docetaxel either trastuzumab lapatinib ( ECH-TH vs. ECL-TL ) patient Her-2 positive primary breast cancer ( Setting III ) . Secondary objective : 1 . To assess toxicity compliance six treatment . 2 . To determine response rate breast tumor axillary node physical examination imaging test ( sonography , mammography , MRI ) treatment arm . 3 . To determine breast conservation rate treatment . 4 . To determine ( loco-regional distant ) disease-free overall survival treatment . In Her-2 positive disease , cerebral disease-free survival determine separately . 5 . To assess treatment efficacy subgroup define accord tumor stage ( T2-3 vs. T4 ) , receptor status ( ER / PgR positive vs. ER PgR negative ) response best appropriate imaging method first four cycle treatment ( complete vs. partial vs. change ) . 6 . To examine compare pre-specified molecular marker Ki-67 , phospho-mTOR , YB-1 , COX-2 , HuR , phospho-p70 S6K , p65 NF kappa B , PTEN , PI3-K , Akt , marker stem cell like breast cancer ( SOX-10 ) core biopsy end chemotherapy . Objectives Substudies : 1 . To assess correlate circulate tumor cell proteins effect treatment ( CTC Substudy ) . 2 . To compare pathologic complete response ( pCR ) , breast conservation , clinical image response rate ( four cycle surgery ) patient tumor show favorable profile predetermine combined biomarker set tumor show ( PREDICT Substudy ) . 3 . To determine percentage patient conventional axillary clearance substitute sentinel node biopsy predetermine clinical algorithm use ( SENTINA Substudy ) . 4 . To assess surgical outcome accord patient 's surgeon 's perspective correlation clinical pathological response systemic treatment ( SOS - Surgical Outcome Substudy ) . 5 . To correlate Single Nucleotide Polymorphisms ( SNPs ) gene either involved metabolism effectiveness distinct therapy associate toxicity histologically assessed treatment effect ( Pharmacogenomic Substudy ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Written inform consent 2 . Complete baseline documentation send GBG Forschungs GmbH ; 3 . Unilateral bilateral primary carcinoma breast , confirm histologically core biopsy . Fineneedle aspiration sufficient . Incisional biopsy allow . 4 . Tumor lesion breast palpable size ≥ 2 cm sonographically size least 1 cm maximum diameter . The lesion measurable twodimensions preferably sonography . In case inflammatory disease extent inflammation use measurable lesion ; 5 . Patients stag disease adjuvant chemotherapy would consider . Locally advanced tumor cT4 cT3 Estrogen ( ER ) progesterone ( PgR ) receptor negative tumor ER PgR positive tumor cN+ ( cT2 ) pNSLN+ ( cT1 ) * During RunInSafety phase patient cT4 cT3 cN+ disease eligible . 6 . Known HER2/neu status detect core biopsy . HER2/neu positive define HercepTest IHC 3+ FISH+ ; 7 . Age old 18 year ; 8 . Karnofsky Performance status index least 80 % ; 9 . Normal cardiac function must confirm ECG cardiac ultrasound ( LVEF shorten fraction ) within 1 month prior registration . 10 . Laboratory requirement : Hematology : Absolute neutrophil count ( ANC ) ≥ 2.0 x 10e9/L platelet ≥ 100 x 10e9/L , Hemoglobin ≥ 10 g/dL ( ≥ 6.2 mmol/L ) Hepatic function : Total bilirubin &lt; 1 x UNL ASAT ( SGOT ) ALAT ( SGPT ) ≤ 2.5 x UNL Alkaline phosphatase ≤ 5 UNL . Patients ASAT / ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study ; Renal function : Creatinine ≤ 175 µmol/L ( 2 mg/dL ) &lt; 1,25 UNL ( calculate creatinine clearance ≥ 60 mL/min ) Urine dipstick proteinuria &lt; 2+ . Patients discover ≥2+ proteinuria dipstick urinalysis undergo 24 hour urine collection must demonstrate ≤1 g protein 24 hour 11 . Paraffin tumor tissue block two serum sample centrally make available 12 . Negative pregnancy test ( urine serum ) 13 . Complete stag workup within 3 month prior registration . 14 . Patients must available compliant treatment followup . Exclusion criterion : 1 . Patients low moderate risk , doubtful candidate adjuvant chemotherapy 2 . Evidence distant metastasis ; 3 . Prior chemotherapy malignancy ; 4 . Prior radiation therapy breast cancer ; 5 . Pregnant lactating patient . 6 . Inadequate general condition 7 . Previous malignant disease 8 . Known suspected congestive heart failure ( &gt; NYHA I ) and/or coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , un poorly control arterial hypertension , rhythm abnormality require permanent treatment , clinically significant valvular heart disease 9 . Previous thromboembolic event 10 . Known hemorrhagic diathesis increase bleed risk 11 . History significant neurological psychiatric disorder would prohibit understanding give informed consent ; 12 . Preexisting motor sensory neuropathy severity grade 2 NCI criterion 13 . Currently active infection ; incomplete wound heal 14 . Active peptic ulcer 15 . Disease significantly affect gastrointestinal function 16 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrollment 17 . Severe pulmonary condition/illness 18 . Unstable diabetes mellitus ; insulin dependent type II diabetes mellitus 19 . Major surgery incomplete wound heal within last 28 day 20 . Definite contraindication use corticosteroid 21 . Known hypersensitivity reaction one investigational compound incorporated substance ; know dihydropyrimidine dehydrogenase deficiency 22 . Concurrent treatment : chronic corticosteroid unless initiate &gt; 6 month prior study entry low dose ( 20 mg methylprednisolone equivalent ) ; sex hormones.Virostatic agent like sorivudine analog like brivudine , concurrent treatment aminoglycosides ; anticoagulant : heparin , warfarin well acetic acid ( e.g . Aspirin® ) dose &gt; 325mg/day clopidogrel dose &gt; 75 mg/day ) e.other experimental drug anticancer therapy ; drug recognize strong inhibitor inducer isoenzyme CYP3A ( e.g . Rifabutin , Rifampicin , Clarithromycin , Ketoconazole , Itraconazole , Ritonavir , Telithromycin , Erythromycin , Verapamil , Dilitazem , within last 5 day expect need treatment study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>primary systemic therapy</keyword>
	<keyword>pCR Rates</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Everolimus</keyword>
</DOC>